CompletedNCT02647437
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
It focuses on schizophrenia and currently lists study information in the United States.
SchizophreniaDrugFrom 18 Years to 65 Years
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Aurora, United StatesSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateJune 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02647437
- Official title
- Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia
Recruitment & locations
CompletedAurora
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Did this study involve medication?
Yes. The study involved medication, including Levetiracetam and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedNCT06880328
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia
This study is completed in the United States. It focuses on schizophrenia.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.